Rob Williams

🚨 A VITAMIN D-BASED DRUG MAY HELP BREAK PANCREATIC CANCER’S HIDDEN DEFENSE — AND THE RESULTS ARE RAISING HOPES Pancreatic cancer is among the deadliest forms of cancer, partly because tumors can surround themselves with a thick layer of supportive tissue. This barrier, made largely of cells called fibroblasts, creates a hostile environment that can keep cancer-fighting immune cells out and make treatment more difficult. But scientists may have found a way to weaken this defense. In a clinical trial, researchers tested paricalcitol, a drug related to vitamin D, alongside standard chemotherapy. The drug is already approved for certain complications of chronic kidney disease. Instead of attacking cancer cells directly, it was designed to change the environment surrounding the tumor — potentially turning the cancer’s own protective territory into a place where treatment could work more effectively. The early results were striking. Among 24 patients with previously untreated metastatic pancreatic cancer who received paricalcitol alongside chemotherapy, 10 experienced partial tumor shrinkage. In the comparison group, which included 12 patients receiving chemotherapy without paricalcitol, only one experienced a partial response. But the most intriguing finding may have been what happened inside the tumors. The treatment appeared to reduce the activity of cancer-associated fibroblasts, helping immune cells called T cells penetrate deeper into the tumor tissue. In other words, researchers weren't simply trying to attack the cancer harder — they were trying to dismantle the defenses that help it survive. There was, however, an important caution. Some patients developed elevated calcium levels, requiring adjustments to their treatment. And because this was an early-phase trial involving just 36 patients, the findings do not yet prove that paricalcitol helps people live longer. Still, the research points toward a fascinating possibility: What if the key to fighting certain cancers is not just destroying the tumor, but first removing the protection that surrounds it? For a disease as difficult to treat as pancreatic cancer, changing the battlefield itself could open a promising new direction for future therapies. Larger studies will be needed to determine whether this approach can deliver lasting benefits. Source: Perez, K. J., et al. (2026). “Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.” Nature Cancer.